COMPANY

CARsgen Therapeutics

Profile checked Oct 10, 2026

Keywords: Pancreatic Cancer Multiple Myeloma Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Relapsed or Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma HCC Pancreatic Adenocarcinoma Primary Plasma Cell Leukemia Refractory B-Cell Non-Hodgkin Lymphoma Relapsed B-cell Non-Hodgkin Lymphoma Hepatocellular Carcinoma Lung Squamous Cell Carcinoma Zevorcabtagene Autoleucel CT041 AB011 CT071 CAR-BCMA T Cells zevor-cel CAR-CD19 T Cells CAR-GPC3 T Cells

13Trials (company is sponsor)

Timeline

Mar 31, 2025 Trial start —: Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy source ↗
2024-10 Trial start —: A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma source ↗
Apr 15, 2024 Trial start Phase 1/Phase 2: Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL source ↗
Oct 8, 2023 Trial start Phase 1: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection source ↗
Jul 11, 2023 Trial start Phase 1: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer source ↗
Oct 23, 2020 Trial start Phase 1/Phase 2: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection source ↗
Oct 23, 2020 Trial start Phase 1/Phase 2: Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers source ↗
Jun 4, 2020 Trial start Phase 1: Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors source ↗
Sep 25, 2019 Trial start Phase 1/Phase 2: Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) source ↗
Aug 15, 2019 Trial start Phase 1: Chimeric Antigen Receptor T Cells Targeting Glypican-3 source ↗
Aug 14, 2019 Trial start Phase 1/Phase 2: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma source ↗
Jun 10, 2019 Trial start Phase 1/Phase 2: Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) source ↗
2016-03 Trial start Phase 1: Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 1 · CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection · NCT06560827
Dec 31, 2026 (ESTIMATED) · Phase 1 · A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer · NCT05911217
Jun 15, 2027 (ESTIMATED) · Phase 1/Phase 2 · Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL · NCT06333509
Dec 31, 2027 (ESTIMATED) · · A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma · NCT06659770
Dec 31, 2039 (ESTIMATED) · · Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy · NCT06825845

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT04581473	Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection	Phase 1/Phase 2	Active, not recruiting	Oct 23, 2020	Oct 18, 2024 (actual)
NCT06825845	Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy	Not listed	Not yet recruiting	Mar 31, 2025	Dec 31, 2039 (estimated)
NCT04404595	Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers	Phase 1/Phase 2	Active, not recruiting	Oct 23, 2020	Jun 1, 2025 (estimated)
NCT06659770	A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma	Not listed	Not yet recruiting	2024-10	Dec 31, 2027 (estimated)
NCT06560827	CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection	Phase 1	Recruiting	Oct 8, 2023	Dec 31, 2026 (estimated)
NCT05911217	A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer	Phase 1	Recruiting	Jul 11, 2023	Dec 31, 2026 (estimated)
NCT04400383	Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors	Phase 1	Completed	Jun 4, 2020	Jul 8, 2023 (actual)
NCT06333509	Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL	Phase 1/Phase 2	Not yet recruiting	Apr 15, 2024	Jun 15, 2027 (estimated)
NCT03975907	Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Jun 10, 2019	Dec 31, 2024 (estimated)
NCT03915184	Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)	Phase 1/Phase 2	Active, not recruiting	Sep 25, 2019	Dec 31, 2024 (estimated)
NCT03994913	Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma	Phase 1/Phase 2	Completed	Aug 14, 2019	Jan 20, 2021 (actual)
NCT03884751	Chimeric Antigen Receptor T Cells Targeting Glypican-3	Phase 1	Completed	Aug 15, 2019	May 28, 2021 (actual)
NCT02876978	Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma	Phase 1	Unknown status (ClinicalTrials.gov)	2016-03	2017-10 (estimated)